Breast Cancer and the Environment Report offers research roadmap

The release of the Institute of Medicine's Breast Cancer and the Environment: A Life Course Approach report has generated quite a bit of interest. Many are expecting information on BPA, pollution and cosmetics; what we get is that there needs to be more research.

The committee defined "environmental" as most non-hereditary causes of cancer. Many of the environment factors it discusses that are preventable are those that can be changed by lifestyle. In addition to exercising more, drinking less alcohol and avoiding tobacco use, the report did mention some other notable topics:

? Forego hormone therapy replacement – when the WHI study results were published in 2002 linking HRT to breast cancer, many women taking HRT for menopausal symptoms stopped taking the drug, and the rate of breast cancer significantly dropped.

? Reduce radiation exposure – this doesn't mean not going through the X-ray machine at the airport when you travel for the holidays nor does it mean cutting back on screening mammograms. But if you don't need a full body CT scan every year, it's probably not a good idea to get one.

Some things the report didn't include as environmental carcinogens are probably noteworthy in itself, such as cosmetics and BPA (Bisphenol A).

Instead the report outlined future methods to studying environmental causes, suggesting that the way most studies are conducted isn't adequate. This we know because of the back-and-forth, contradictory studies on everything from cell phones to supplements. The committee recommends looking into exposures over the course of a lifetime (hence the report's title), including in utero, while also taking into account the combination and mixture of chemicals, interplay between genetics and environmental toxins, and length of exposure and age when exposed. These are difficult topics to study and will take a lot of time and money before we have anything meaningful.

"We know that breast cancer is influenced by hormones, and estrogen exposure is a risk factor," said Irva Hertz-Picciotto, PhD, chair of the committee. "A number of compounds are active estrogenically - those are opportunities for potentially reducing risk. BPA is one of those compounds," and therefore, she says, deserves more research attention. Currently, there is little to no epidemiological research on BPA and cancer risk. Other possible breast carcinogens that need more research are benzene and night-shift work. Some expressed disappointment that the report didn't turn up more definitive answers and prevention strategies.

"What we found was that the evidence base wasn't there to say these (other factors) contribute to breast cancer. I think we were all disappointed to not be able to recommend more," said Herz-Picciotto during the presentation's question-and-answer Wednesday afternoon.

The report was funded by Susan G. Komen for the Cure. If you'd like to download the free pdf of the report, go to

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
//For side ad protocol